Zobrazeno 1 - 10
of 57
pro vyhledávání: '"A. D Ricart"'
Autor:
R Suau, E Pardina, M D López-Tejero, V Lorén, Y Zabana, M Llaves, B Cordobilla, F Cañete, M Guasch, D Ricart-Jané, M Mañosa, E Domènech, J C Domingo, J Manyé
Publikováno v:
Journal of Crohn's and Colitis. 17:i192-i194
Background Crohn’s disease (CD) is an inflammatory bowel disease (IBD) of complex etiology that normally requires bowel resection. However, many patients suffer from post-operative recurrence (POR) within one year. Here, the inflammatory and bacter
Autor:
Karen Kelly, Lincoln Nadauld, Vivek Subbiah, Davendra Sohal, Howard Safran, Julio Antonio Peguero, Alejandro D. Ricart, Erica Stealey, Juneko E. Grilley-Olson, Das Purkayastha, Joseph Paul Eder, Bert H. O'Neil, Barinder P. Kang
Publikováno v:
JCO precision oncology. 3
PURPOSE As part of the Novartis Signature Program, this study evaluated the efficacy of ribociclib (selective cyclin-dependent kinase 4/6 [CDK4/6] inhibitor) in patients with cyclin D–CDK4/6 pathway–aberrant tumors. METHODS This was a phase II, s
Publikováno v:
Canadian Journal of Forest Research. 50:126-135
Understanding how plant community assemblage is affected by spatial and temporal patterns is crucial to understanding forest ecosystem responses to disturbance, including future climate change. In this article, we tracked how diversity and compositio
Autor:
R. S. D. Ricart, Rodrigo Miloni Santucci, C. E. M. Oliveira, G. F. Degrazia, Marco Brandalise de Andrade, W. R. Nava
Publikováno v:
Historical Biology. 33:1012-1023
The Upper Cretaceous Bauru Group deposits furnished several species of Crocodylomorpha, especially notosuchians. However, little is known about the feeding habits of this diverse group of crocodylo...
Autor:
Stanley Cheung, H.P. Miskin, Tomasz Wróbel, Owen A. O'Connor, Krzysztof Giannopoulos, Wojciech Jurczak, C. K Yannakou, C.Y. Cheah, A. D Ricart, Nicholas Wickham, J. P. Tang, M. Lasica, Katharine L Lewis, Jan Walewski, Constantine S. Tam, E. Normant, M. Długosz-Danecka
Publikováno v:
Hematological Oncology. 39
Introduction: TG-1701 is a selective, covalent BTK inhibitor administered once daily (QD). Both the “U2” combination (anti-CD20 mAb ublituximab + the PI3Kδ-CK1ϵ inhibitor umbralisib) and BTK inhibition are highly active in treatment-naive (TN)
Autor:
Monika Raut, Arun Balakumaran, Jinan Liu, Matthew J. Monberg, Xiting Cao, Changxia Shao, Wei Zhou, Alejandro D. Ricart
Publikováno v:
Leukemia & Lymphoma. 60:947-954
Data are limited on the real-world utilization and costs of brentuximab vedotin (BV) among patients with relapsed/refractory Hodgkin lymphoma (rrHL) in the United States. A total of 219 BV patients identified from the Truven MarketScan® databases we
Autor:
Monika Długosz-Danecka, Constantine S. Tam, Wojciech Jurczak, Masa Lasica, Costas K. Yannakou, Hari P. Miskin, Alejandro D. Ricart, Chan Yoon Cheah, Jan Walewski, Katharine L Lewis, Krzysztof Giannopoulos, Stanley Cheung, Owen A. O'Connor, Tomasz Wróbel
Publikováno v:
Blood. 138:1549-1549
Introduction: TG-1701 is an irreversible, selective, novel Bruton's tyrosine kinase inhibitor (BTKi) administered once daily (QD). BTK inhibitors, as well as the U2 combination (anti-CD20 mAb ublituximab + the PI3Kδ-CK1ε inhibitor umbralisib), are
Autor:
Stephen J. Murphy, Simon A. Queenborough, Meghna Krishnadas, Alexander T. Fotis, R. D. Ricart, John W. Wenzel, James Whitacre, Liza S. Comita
Publikováno v:
Journal of Ecology. 106:561-570
Summary 1.Forest ecosystems are critical for the global regulation of carbon (C), a substantial portion of which is stored in aboveground biomass (AGB). While it is well understood that taxonomic and functional composition, stand structure, and envir
Autor:
Glenn Liu, Patricia LoRusso, Elisabeth I. Heath, Yanwei Zhang, Justine Yang Bruce, Elizabeth A. Sadowski, David R. Shalinsky, Michael A. Tortorici, Aurora Breazna, Anne M. Traynor, Priscila H. Goncalves, Alejandro D. Ricart
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:527-538
PURPOSE: PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity o
Autor:
Emmanuel Normant, Costas K. Yannakou, Katharine L Lewis, Alejandro D. Ricart, Jian-Ping Tang, Hari P. Miskin, Nicholas Wickham, Chan Yoon Cheah, Constantine S. Tam, Chi-Hung Hui, Tejasvi Turpuseema, Pek Sang Tang
Publikováno v:
Blood. 134:4001-4001
Introduction Agents targeting BTK have demonstrated activity in a variety of B-cell malignancies, however not all patients respond to therapy, and amongst those that do respond, complete remissions are rare. BTK-based combination regimens have the po